Core Viewpoint - The National Medical Products Administration (NMPA) has approved 10 innovative medical devices for special review procedures as part of the third batch of applications for 2026 [1][2] Group 1: Approved Innovative Products - The following innovative products have been granted special review status: 1. Chronic Obstructive Pulmonary Disease Assessment Software by Bojiang Life Sciences (Shanghai) Co., Ltd. [1][2] 2. Ultrasound Therapy Device by Shenzhen Tengfu Medical Technology Co., Ltd. [1][2] 3. Transcatheter Artificial Tricuspid Valve by Edwards Lifesciences LLC [1][2] 4. Transcatheter Artificial Tricuspid Valve by Jiangsu Zhenyi Medical Technology Co., Ltd. [1][2] 5. Ultrasound Thrombolysis Catheter and Stent System by Shanghai Tengfu Medical Technology Co., Ltd. [1][2] 6. Radiation Therapy Planning Software by Guoke Ion Medical Technology Co., Ltd. [1][2] 7. Implantable Cardioverter Defibrillator by Chuangling Cardiac Rhythm Management Medical Device (Shanghai) Co., Ltd. [1][2] 8. Peripheral Balloon Expandable Stent System by Zhejiang Guichuang Medical Technology Co., Ltd. [1][2] 9. Thoracoabdominal Endoscopic Surgical System by Zhi Guan Medical Company [1][2] 10. Coronary Sinus Balloon Counterpulsation System by Shanghai Micron Melody Medical Technology Co., Ltd. [1][2]

Core Viewpoint - The article discusses the recent approval of 10 innovative medical devices by the National Medical Products Administration (NMPA) in China, highlighting the advancements in the medical technology sector and the companies involved in these innovations [1]. Group 1: Innovative Medical Devices - The first product is a software for assessing chronic obstructive pulmonary disease, developed by Bojiang Life Sciences (Shanghai) Co., Ltd., which focuses on digital biomarkers and therapies for chronic disease management [2]. - The second product is an ultrasound therapy device from Shenzhen Tengfu Medical Technology Co., Ltd., which specializes in interventional devices for pulmonary embolism treatment [3]. - The third product is a transcatheter artificial tricuspid valve developed by Edwards Lifesciences, a leading company in structural heart disease devices [4][5]. - The fourth product is an ultrasound thrombolysis catheter and stent system from Shanghai Tengfu Medical Technology Co., Ltd., aimed at providing safer treatment options for venous thromboembolism [9][11]. - The fifth product is a radiation therapy planning software from Guoke Ion Medical Technology Co., Ltd., which focuses on the industrialization of medical heavy ion technology [12]. - The sixth product is an implantable cardioverter-defibrillator from Chuangling Heart Rhythm Management Medical Device (Shanghai) Co., Ltd., which aims to provide high-quality heart rhythm management products [13]. - The seventh product is a peripheral balloon-expandable stent system from Zhejiang Guichuang Medical Technology Co., Ltd., which specializes in high-end vascular interventional devices [14]. - The eighth product is a thoracoabdominal endoscopic surgical system from Intuitive Surgical, a global leader in robotic-assisted minimally invasive surgery [15][16]. - The ninth product is a coronary sinus balloon counterpulsation system from Shanghai Micron Melody Medical Technology Co., Ltd., which focuses on coronary intervention devices [17].

Core Viewpoint - Betaini is re-entering the high-end beauty device market by revamping the TriPollar brand and establishing an operational team to enhance its product offerings and technology capabilities [2][3]. Group 1: Company Strategy - Betaini is building an operational team for the TriPollar brand, led by Vice General Manager Zhang Mei, and is actively recruiting for various positions related to e-commerce and media [2]. - The collaboration with TriPollar aims to create a synergistic product offering that combines devices, gels, and post-care solutions, covering both home use and medical aesthetics [3]. Group 2: Market Position and Challenges - TriPollar, a high-end home beauty device brand from Israel, has faced challenges, including a recall of over 180,000 units due to temperature control defects and the need for regulatory compliance as a Class III medical device [15][16]. - As of 2025, TriPollar has not made progress in obtaining the necessary Class III medical device certification, which poses a risk of being banned from sale if not achieved by April 2026 [16]. Group 3: Financial Performance - Betaini's market capitalization has significantly declined from a peak of 120 billion yuan to approximately 19.4 billion yuan, with its stock price dropping below the initial offering price [18][19]. - The company's revenue growth has slowed considerably, with net profit halving over the past three years, and a 13.51% year-on-year decline in Q1 2025 [21][22]. Group 4: Investment and R&D - In recent years, Betaini has made strategic investments in the beauty device sector, including a 9.49% stake in Weimai Medical, which is developing high-end medical devices [6]. - The company is also enhancing its independent research and development capabilities, with multiple patents related to radiofrequency beauty devices filed since 2024 [10].